Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Petzer

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Cells|July 29, 2023
Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell TransplantationAlexander Nikoloudis, Veronika Buxhofer-Ausch, Christoph Aichinger, et al.
Wiener Klinische Wochenschrift|December 14, 2018
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Cytotherapy|February 22, 2024
Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletionAlexander Nikoloudis, Veronika Buxhofer-Ausch, Christoph Aichinger, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Transplantation and Cellular Therapy|May 15, 2021
Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous RecipientsAlexander Nikoloudis, Helga Wagner, Sigrid Machherndl-Spandl, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Anti-Cancer Drugs|March 27, 2014
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomasKira Brämswig, Ferdinand Ploner, Alexandra Martel, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Cells|July 29, 2023
Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell TransplantationAlexander Nikoloudis, Veronika Buxhofer-Ausch, Christoph Aichinger, et al.
Wiener Klinische Wochenschrift|December 14, 2018
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Cytotherapy|February 22, 2024
Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletionAlexander Nikoloudis, Veronika Buxhofer-Ausch, Christoph Aichinger, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Transplantation and Cellular Therapy|May 15, 2021
Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous RecipientsAlexander Nikoloudis, Helga Wagner, Sigrid Machherndl-Spandl, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Anti-Cancer Drugs|March 27, 2014
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomasKira Brämswig, Ferdinand Ploner, Alexandra Martel, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Pageof 7